INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists’ View

Zahra Maleki; Akash Nadella; Mohnish Nadella; Gopi Patel; Shivni Patel; Ivana Kholová

doi:10.3390/diagnostics11122172

Diagnostics (Nov 2021)

INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists’ View

Zahra Maleki,
Akash Nadella,
Mohnish Nadella,
Gopi Patel,
Shivni Patel,
Ivana Kholová

Affiliations

Zahra Maleki: Division of Cytopathology, Department of Pathology, The Johns Hopkins Hospital, The Johns Hopkins Medical Institution, Baltimore, MD 21218, USA
Akash Nadella: Department of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA
Mohnish Nadella: Department of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA
Gopi Patel: Department of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA
Shivni Patel: Department of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA
Ivana Kholová: Department of Pathology, Fimlab Laboratories, Tampere, Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland

DOI: https://doi.org/10.3390/diagnostics11122172
Journal volume & issue: Vol. 11, no. 12
p. 2172

Abstract

Read online

Background: Insulinoma-associated protein 1 (INSM1) has been considered as a novel immunostain for neuroendocrine tumors (NETs) and is hypothesized to be more reliable than first-generation NET biomarkers, such as CGA (chromogranin A), SYP (synaptophysin) and CD56 (neural cell adhesion molecule). In this review, we summarize existing literature on INSM1′s reliability as an immunostain for detection of various NETs, its results in comparison to first-generation NET biomarkers, and its expression in both non-NETs and benign tissues/cells on cytology specimens (cell blocks/smears).

Published in Diagnostics

ISSN: 2075-4418 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.mdpi.com/journal/diagnostics

About the journal

Abstract

Keywords